Regeneron Pharmaceuticals (REGN) Q4 2024 Annual Earnings
Regeneron Pharmaceuticals reported Q4 2024 revenue of $3.8B, beat analyst consensus of $3.7B by $47.0M. Diluted EPS came in at $12.07, beat the $11.21 consensus by $0.86. Regeneron Pharmaceuticals reports across 4 business segments, led by Ophthalmology, Immunology & Inflammation, and Oncology.
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Regeneron Pharmaceuticals's Q4 2024 earnings report.
Regeneron Pharmaceuticals (REGN) reported Q4 2024 earnings on February 4, 2025 before market open.
Regeneron Pharmaceuticals reported revenue of $3.8B and diluted EPS of $12.07 for Q4 2024.
Revenue beat the consensus estimate of $3.7B by $47.0M. EPS beat the consensus estimate of $11.21 by $0.86.
You can read the 10-K periodic report (0001804220-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.